Printer Friendly

ELAN STEPS UP PROSTEP PATCH PRODUCTION FOR CYANAMID'S LEDERLE; MORE THAN FOUR MILLION SHIPPED THUS FAR

 ELAN STEPS UP PROSTEP PATCH PRODUCTION FOR CYANAMID'S LEDERLE;
 MORE THAN FOUR MILLION SHIPPED THUS FAR
 ATHLONE, Ireland, March 9 /PRNewswire/ -- In response to the strong demand for nicotine patches in the United States, Elan Corporation, plc (AMEX: ELN), is stepping up production of its patented ProStep(TM) nicotine patches for Lederle Laboratories, a division of American Cyanamid (NYSE: ACY), which is marketing the new smoking cessation aid. The product was approved by the U.S. Food and Drug Administration in late January.
 Elan said it set new manufacturing quotas not only in response to ProStep's planned penetration curve, but also in hopes of helping alleviate overall nicotine patch shortages in several parts of the country.
 Several publications including the Wall Street Journal (March 4, 1992) have reported nicotine patch shortages in some areas, with especially tight supplies in certain markets, such as Boston and parts of New Jersey.
 Most Novel Package Format
 Elan's ProStep shipments to the United States to date total more than four million 24-hour patches in weekly packages of seven, versus the two-week and 30-day supply packages for the other approved brands.
 Elan officials note that their novel seven-day packaging format allows for broader distribution, and gives pharmacies greater flexibility in dispensing the product, especially in times of tight supply.
 "We are extremely pleased with the depth and sophistication of Lederle's marketing programs for this product and the success it envisions as evidenced by incoming orders," said Donald E. Panoz, Elan's chairman and chief executive officer. "We are committed to a continuous and uninterrupted flow of ProStep nicotine patches to meet the needs of U.S. smokers who seek a proven way to quit the habit."
 Elan's ProStep patch is one of three currently approved for marketing in the United States. In clinical trials using one single dosage strength, 22mg/day for six to eight weeks, quit rates with ProStep were significantly higher than those seen with placebo, when both were used with counseling.
 Lederle is offering patients who are prescribed ProStep a unique package of support services, including a toll-free hotline manned by smoking cessation specialists and a pharmacist counseling program.
 Elan's 24-hour patch has the lowest loading and highest utilization of nicotine among all nicotine patches currently on the market, minimizing issues of environmental safety with regard to disposal.
 The Elan patch is also marketed in Ireland, South Korea, Southeast Asia and Italy where it is sold over-the-counter. Approvals have been received from three other European countries, Germany, Denmark and Greece, with others expected to be announced.
 Elan Corporation, plc, is a leader in the specialized health care field of advanced reformulations and drug delivery, concentrating on improved drug absorption and utilization. Elan operates research and manufacturing facilities in Athlone, Republic of Ireland; Gainesville, Ga.; Enschede, Netherlands; Manila, Philippines; Brea, Calif.; and Cambridge, Mass.
 -0- 3/9/92
 /CONTACT: Brian Crotty, 800-252-3526, or Thomas Redington, 203-222-7399 or 212-926-1733, both for Elan/
 (ELN ACY) CO: Elan Corporation plc; American Cyanamid ST: IN: MTC SU:


GK-OS -- NY032 -- 6332 03/09/92 10:56 EST
COPYRIGHT 1992 PR Newswire Association LLC
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 1992 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:PR Newswire
Date:Mar 9, 1992
Words:508
Previous Article:BNA PUBLISHES ENVIRONMENTAL DUE DILIGENCE GUIDE
Next Article:AIR NEW ZEALAND OFFERS SPECIAL UPGRADES TO BUSINESS AND FIRST CLASS ON FLIGHTS DOWN UNDER
Topics:


Related Articles
ELAN: COURT REFUSES TO CONTINUE RESTRAINT AGAINST MARION MERRELL DOW
PROSTEP NICOTINE TRANSDERMAL SYSTEM RECEIVES APPROVAL
U.S. FDA APPROVES ELAN'S NICOTINE PATCH
/FIRST ADD -- NY081 -- ELAN'S NICOTINE PATCH APPROVED BY FDA/
ALZA, CYANAMID, ELAN AND MARION MERRELL CONCLUDE AGREEMENTS AND REACH AN OUT-OF-COURT SETTLEMENT
ELAN ADDS $200 MILLION OF NICOTINE PATCH PRODUCTION CAPACITY WITH SECOND UNIT; U.S. MARKET SHARE NOW AT 30 PERCENT
LEDERLE LABORATORIES ISSUES A STATEMENT ON PROSTEP
LEDERLE ANNOUNCES PROSTEP NOW FULLY AVAILABLE; NATIONAL ADVERTISING BEGINS ON THE OLYMPICS THIS WEEK
LEDERLE EXTENDS PROSTEP REBATE THROUGH END OF YEAR TO MAKE PRESCRIPTION NICOTINE PATCH MORE ACCESSIBLE IN LIGHT OF FDA BAN ON OVER-THE-COUNTER...
LEDERLE EXTENDS PROSTEP REBATE THROUGH END OF YEAR TO MAKE PRESCRIPTION NICOTINE PATCH MORE ACCESSIBLE IN LIGHT OF FDA BAN ON OVER-THE-COUNTER...

Terms of use | Copyright © 2016 Farlex, Inc. | Feedback | For webmasters